Wegovy 7.2mg reviews: what patients and trials actually tell us

The decision most people are actually facing at 7.2mg

If you've found yourself scrolling reviews of the 7.2mg dose, the chances are you're already on Wegovy and wondering whether pushing to the higher dose is worth it, or you're comparing it against tirzepatide (Mounjaro) before deciding where to start. That's the real fork in the road, and it's worth being clear about what reviews can and can't tell you.

Online accounts of any medicine tend to cluster at the extremes: people who lost a lot of weight, or people who had a rough time with side effects. The people in the middle (modest progress, few problems) rarely post. That doesn't make the reviews dishonest, but it does make them unrepresentative. Trial data from thousands of participants gives a more balanced picture of what most people experience, and on this page that's the evidence we draw from.

The MHRA approved the dedicated 7.2mg single-dose pen on 14 April 2026, designed for adults with obesity (BMI 30 or above). Whether the highest dose is appropriate for you specifically is a clinical question, not one a review thread can answer. Our clinical team reviews each consultation individually, without automation.

What the trial evidence shows at 7.2mg (and where anecdotal reviews align

The figure that keeps appearing in reviews from people on the 7.2mg dose, people talking about losing 20% or more of their body weight, tracks closely with the clinical data. Trials at the 7.2mg dose reported approximately 20.7% average weight reduction over 72 weeks. For context, the earlier STEP 1 trial, published in the New England Journal of Medicine, put average loss at around 15% at the 2.4mg maintenance dose over 68 weeks, so the gap is real, not just internet enthusiasm.

People who plateau on 2.4mg and move up often describe a renewed period of loss, which aligns with the dose-response relationship seen across the semaglutide programme. That said, reviews also show a pattern of stronger GI effects when stepping up: nausea and loose stools in the days after a dose increase, generally settling within one to two weeks. That pattern matches what the trial data records.

One thing reviews understandably gloss over: the titration takes time. You don't start at 7.2mg. The prescriber steps you up from 0.25mg, and reaching the top dose takes at least several months. If you want a sense of what earlier stages feel like from a patient perspective, accounts from people on the 1mg dose give a useful window into that part of the journey. For a broader look at how the dosing schedule works across all strengths, the Wegovy doses guide covers the full path.

Side effects at 7.2mg: what reviews flag that you should know

The most consistent theme in 7.2mg reviews, beyond the weight-loss results, is that the GI side-effect burden can increase with the dose step. Nausea, loose stools and reduced appetite (which many people actually welcome) are the most commonly mentioned. In rare cases, more significant effects are reported.

It's worth knowing that in January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 medicines. The signal to act on: severe stomach pain that doesn't ease up and radiates toward the back, especially with vomiting. That warrants same-day medical attention, not watching and waiting. Any suspected side effect can be reported directly through the Yellow Card scheme.

Reviews also sometimes mention injection-site reactions, fatigue in the first few days after a step-up, and (less often) headache. These tend to be short-lived. The NHS patient information for semaglutide covers the full side-effect profile clearly, it's worth reading before or during treatment.

If you're considering the cost side of this decision alongside the clinical question, the Wegovy cost page sets out how UK private pricing typically works and what a legitimate prescription service includes.

How semaglutide 7.2mg fits into the wider treatment picture

For some people, 7.2mg closes a lot of the gap between Wegovy and tirzepatide results. The SURMOUNT-5 trial showed tirzepatide producing greater average weight reduction than semaglutide 2.4mg head-to-head, but at 7.2mg the results are considerably closer. Which medicine suits a particular person (taking into account their health history, any other medicines they take, and their goals) is the kind of nuanced conversation that belongs in a consultation, not in a comparison chart.

The Wegovy overview covers the full context of how semaglutide is licensed and used in the UK. If you've been on a lower dose and found it underwhelming, reading what people share about their experience at 0.5mg can help you gauge whether early underwhelm is normal before deciding whether to continue toward higher doses. The picture at 7.2mg is genuinely different from where this medicine started, and the clinical evidence supports that, not just the review threads.

When you order through a regulated service like nume, you'll know what to expect: your treatment arrives the next working day via DPD, tracked, in plain unbranded packaging. No surprises. Our prescribers also review progress before every repeat order, so any conversation about dose is built into the process. If you'd like a clinical assessment to see whether Wegovy could be right for you, you're welcome to check your eligibility with a free consultation.